In this study, we showed that the use of BEV can abrogate the tumor‐promoting effect of VMP1 in GBM, and that targeting VMP1 or VMP1‐associated pathways may serve as a novel therapeutic approach, either in combination with or as an alternative to BEV. Here, VMP1 is linked to glioblastoma.